Phase 2 Crohn's Disease and Colitis Trial, Recruiting NCT04224558 Sponsor: Cedars-Sinai Medical Center Condition: Crohn's Disease and Colitis
Back to Crohns Disease And Colitis

Phase 2 Crohn's Disease and Colitis Trial, Recruiting

NCT04224558
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 13 and 28 years old
  • You have been diagnosed with Crohn's disease for at least 6 months before joining, confirmed by scans or tissue samples
  • Your Crohn's disease is currently active, shown by a disease activity score above 30, plus at least two of the following: raised inflammation levels in your blood, a camera test (endoscopy) showing active disease confirmed by tissue samples, or a CT or MRI scan clearly showing active Crohn's disease in the small bowel
  • Your disease has not been well controlled despite trying at least 3 different immune-suppressing medications (such as azathioprine, methotrexate, infliximab, adalimumab, or certolizumab) as well as steroids, or you have had serious side effects from these medications
  • Surgery is not a suitable option for you, or surgery could leave you at risk of having too little bowel remaining to absorb food properly
  • You have been reviewed and approved as a suitable candidate by the specialist bowel disease team at the trial centre
  • You are willing to give your informed consent, take part in additional study visits and tests, and have received thorough counselling about the risks involved

Who may not be able to join:

  • You are pregnant, or you are not willing to use reliable contraception during the study (this applies to both women who could become pregnant and men)
  • You have serious kidney problems (confirm with trial site)
  • You have serious heart problems, such as severe heart failure, a weakened heart, uncontrolled irregular heartbeat, or fluid around the heart causing problems (confirm with trial site)
  • Your lungs are not working well enough, specifically if your lung diffusion capacity is below 40% (confirm with trial site)
  • You have a psychiatric condition, or are currently misusing alcohol or drugs
  • You have, or have recently had, cancer (except for certain common skin cancers)
  • You have high blood pressure that remains uncontrolled despite taking at least two blood pressure medications
  • You have HIV, HTLV-1 or 2, hepatitis, or any other infection the medical team considers a reason not to participate
  • You have another long-term illness causing major organ damage
  • You currently have a significant abscess or serious active infection
  • You have a perianal fistula (a tunnel near your back passage) that is not draining freely and has not been surgically managed (confirm with trial site)
  • You have a history of tuberculosis (TB), are currently at increased risk of TB, or have test results suggesting active TB
  • Your chest X-ray shows signs of active infection or a tumour
  • You are significantly underweight, with a BMI of 18 or below, or very low protein levels in your blood
  • You have a history of not following medical treatment plans as agreed
  • You are currently taking part in another clinical trial using an experimental drug, or have done so within the past four weeks

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 7 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: David Ziring, MD, Cedars-Sinai Medical Center

Phone: 310-423-7100

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Cedars-Sinai Medical Center
Registry
ClinicalTrials.gov
Start date
15 November 2019
Est. completion
30 September 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in mucosal healing; Change in erythrocyte sedimentation rate (SED rate); Change in fecal calprotectin concentration; Change in C reactive protein (CRP); Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]; Incidence of HSCT Related Complications; Change in clinical measures of sustained remission

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov